Abstract
INTRODUCTION The pandemic readiness toolbox needs to be extended, providing diagnostic tools that target different biomolecules, using orthogonal experimental setups and fit-for-purpose specification of detection. Here we build on a previous Cov-MS effort that used liquid chromatography-mass spectrometry (LC-MS) and describe a method that allows accurate, high throughput measurement of SARS-CoV-2 nucleocapsid (N) protein.
MATERIALS and METHODS We used Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) technology to enrich and quantify proteotypic peptides of the N protein from trypsin-digested samples from COVID-19 patients.
RESULTS The Cov2MS assay was shown to be compatible with a variety of sample matrices including nasopharyngeal swabs, saliva and blood plasma and increased the sensitivity into the attomole range, up to a 1000-fold increase compared to direct detection in matrix. In addition, a strong positive correlation was observed between the SISCAPA antigen assay and qPCR detection beyond a quantification cycle (Cq) of 30-31, the level where no live virus can be cultured from patients. The automatable “addition only” sample preparation, digestion protocol, peptide enrichment and subsequent reduced dependency upon LC allow analysis of up to 500 samples per day per MS instrument. Importantly, peptide enrichment allowed detection of N protein in a pooled sample containing a single PCR positive sample mixed with 31 PCR negative samples, without loss in sensitivity. MS can easily be multiplexed and we also propose target peptides for Influenza A and B virus detection.
CONCLUSIONS The Cov2MS assay described is agnostic with respect to the sample matrix or pooling strategy used for increasing throughput and can be easily multiplexed. Additionally, the assay eliminates interferences due to protein-protein interactions including those caused by anti-virus antibodies. The assay can be adapted to test for many different pathogens and could provide a tool enabling longitudinal epidemiological monitoring of large numbers of pathogens within a population, applied as an early warning system.
Competing Interest Statement
Van Oudenhove L., Van Hulle M., Claereboudt J., Wyndham K, and Vissers J.P.C. are employed by Waters Corporation. Razavi M., Yip Y., Pearson TW. and Anderson N.L. are employed by SISCAPA Assay Technologies Inc.
Funding Statement
This research was funded by grants from the Research Foundation Flanders (FWO): B.V.P (grant number 11B4518N), R.G. (grant number 1S50918N), L.M. (grant number G042518N), and M.D. (12E9716N); A BOF-COVID-19 grant from the University Ghent Special Research Funding (BOF - 01C01920) and a grant from the European Unions Horizon 2020 Programme under Grant Agreement 823839 (H2020-INFRAIA-2018-1). Work at SISCAPA Assay Technologies Inc. at the University of Victoria was supported in part by an NSERC (Canada) grant awarded to Dr. Caroline Cameron. A.M. is supported by a PhD student fellowship from the FWO and T.V.R by FWO EOS project VIREOS granted to X.S. The authors thank Dr. Cameron for her advice and contributions to our research. Andrea Bhangu-Uhlmann and Florian C. Sigloch from Polyquant GmbH are acknowledged for providing us with the Cov-MS QconCAT.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of University Hospital Ghent gave ethical approval for this work (BC-09263)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The mass spectrometry MRM and DIA-MS proteomics data have been deposited to the ProteomeXchange Consortium via the Panorama Public partner repository with the dataset identifier, PXD031401. However, direct access can be obtained by clicking on the following link: https://panoramaweb.org/Cov2MS.url.
